Summary
The InDx CMC Implant is for the treatment of thumb base joint arthritis. It is the first evidence-based, surgeon-led innovation, implant solution for this major clinical problem. The potential market is estimated at over €700M per year.
The implant meets a major unmet clinical need for an ageing EU population.
The implant re-creates the natural joint biomechanics to give a more reliable and clinically superior outcome for patients. This disruptive technology can change the treatment landscape for this condition. The implant provides an exciting new treatment option for an under-served population. It has been shown to eliminate pain and restore full joint mobility.
The InDx Implant is smarter, safer, and simpler to insert than any current treatment options.
The InDx Implant is patented, with a clear pathway to regulatory clearance in the EU and US.
The company is led by a physician-innovator and is supported by medical device industry veterans and world-leading hand surgeons.
The implant meets a major unmet clinical need for an ageing EU population.
The implant re-creates the natural joint biomechanics to give a more reliable and clinically superior outcome for patients. This disruptive technology can change the treatment landscape for this condition. The implant provides an exciting new treatment option for an under-served population. It has been shown to eliminate pain and restore full joint mobility.
The InDx Implant is smarter, safer, and simpler to insert than any current treatment options.
The InDx Implant is patented, with a clear pathway to regulatory clearance in the EU and US.
The company is led by a physician-innovator and is supported by medical device industry veterans and world-leading hand surgeons.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190131605 |
| Start date: | 01-11-2022 |
| End date: | 30-04-2024 |
| Total budget - Public funding: | 3 658 337,50 Euro - 2 500 000,00 Euro |
Cordis data
Original description
The InDx CMC Implant is for the treatment of thumb base joint arthritis. It is the first evidence-based, surgeon-led innovation, implant solution for this major clinical problem. The potential market is estimated at over €700M per year.The implant meets a major unmet clinical need for an ageing EU population.
The implant re-creates the natural joint biomechanics to give a more reliable and clinically superior outcome for patients. This disruptive technology can change the treatment landscape for this condition. The implant provides an exciting new treatment option for an under-served population. It has been shown to eliminate pain and restore full joint mobility.
The InDx Implant is smarter, safer, and simpler to insert than any current treatment options.
The InDx Implant is patented, with a clear pathway to regulatory clearance in the EU and US.
The company is led by a physician-innovator and is supported by medical device industry veterans and world-leading hand surgeons.
Status
SIGNEDCall topic
HORIZON-EIC-2022-ACCELERATOROPEN-01Update Date
31-07-2023
Geographical location(s)
